Almirall spots an opportunity
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
Upcoming events – Antibiotics from Insmed and Paratek face consecutive panels
Make-or-break FDA adcoms beckon for two antibiotics.
